Samir Hanash

This study identifies KRAS-driven metabolic reprogramming through MFSD2A-mediated lysophosphatidylcholine scavenging as a driver of PDAC progression and shows that targeting this pathway with edelfosine has anti-cancer effects.

This study identifies YAP1-positive cells in relapsed SCLC that exhibit drug tolerance and transition from SCLC to LCNEC-like features, losing some targets but gaining others.

The paper identifies a metabolic vulnerability in triple-negative breast cancer through sphingolipid metabolism, showing that targeting this pathway with eliglustat reduces tumor growth and improves survival.

This study identifies the YAP1-SDC1 axis as a driver of resistance to mKRAS inhibitors in gastrointestinal cancers and suggests targeting this axis to overcome resistance.

This study identifies aberrant CD14 expression in breast tumor cells as a marker of poor clinical outcomes and aggressive disease.

This study evaluates combinations of PDAC biomarkers across multiple labs, finding improved sensitivity and specificity for early-stage detection compared to CA19-9 alone.

The paper introduces SMAGS, a regression framework that maximizes sensitivity at a given specificity for binary classification, showing 14% improvement in sensitivity on a colorectal cancer dataset.

The paper uses computational methods to classify gene expression profiles into epithelial, hybrid E/M, and mesenchymal categories based on EMT dynamics and scoring metrics.